IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4021
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$137M
Jaisim Shah
Vickers Vantage Corp. I does not have significant operations. The company was incorporated in 2020 and is based in Singapore. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or reorganization.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$SCLX Scilex Holding Co | 36 | 37 | 4 | 52 | - | - | 171.0% | -120.5% | 70.4% | -667.2% | -859.5% | -35.5% | 0.0% | - | $137M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Scilex Holding Co (SCLX) receives a "Avoid" rating with a composite score of 35.9/100. It ranks #4021 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for SCLX.
View All RatingsROIC -328.9% vs WACC 7.6% (spread -336.5%)
GM 70% vs sector 44%, OM -667% vs sector 3%
Capital turnover 0.24x, R&D intensity 49.3%
Rev growth -35%, 5yr history
Interest coverage -66.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Scilex Holding Co (SCLX) as Avoid with a composite score of 35.9/100 at a current price of $7.68. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Scilex Holding Co holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.9/100 places it at rank #4021 in our full universe.
No Moat
Medium
Poor
Fair Value
Gross margins of 70% signal strong pricing power.
Returns on equity of 171.0% exceed cost of capital.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
Scilex Holding Co represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Scilex Holding Co with an Avoid rating, assigning a composite score of 35.9/100 and 1 out of 5 stars. Ranked #4021 of 7,333 stocks, SCLX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
SCLX's quality score of 37/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 171.0% (sector avg: -1.9%), gross margins of 70.4% (sector avg: 44.1%), net margins of -859.5% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
SCLX registers a value score of just 4/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Scilex Holding Co's investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -35.5% vs. a sector average of 6.7% and a return on assets of -120.5% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
SCLX demonstrates moderate momentum with a score of 52/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -35.5% year-over-year, while a beta of -2.24 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
SCLX's stability score of 34/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -2.24. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 49/100 for SCLX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $137M market cap (micro-cap), Scilex Holding Co may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Scilex Holding Co is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4021 of 7,333 overall (45th percentile). Key comparisons include ROE of 171.0% exceeding the -1.9% sector median and operating margins of -667.2% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While SCLX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (4) would have the largest impact on the composite score.
ROE 9102% BELOW SECTOR MEDIAN
Gross Margin 60% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 26683% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Scilex Holding Company ( NASDAQ:SCLX ) shareholders won't be pleased to see that the share price has had a very rough...
Key Insights The considerable ownership by retail investors in Scilex Holding indicates that they collectively have a...
The latest investor updates on stocks that are trending on Monday
Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, closing out option agreement obligations and bringing total returns to $118 million on its original $99.5 million investment. The company's board approved a $0.25 per share cash dividend (~$10.5 million aggregate) to be paid on January 26, 2026. Oramed retains $39 million in outstanding debt, convertible notes, warrants, and royalty interests with Scilex.